Caris Life Sciences, Inc.
CAINASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $8.98B
- P/E (TTM)
- 85.87
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $14.19$33.65
- Volume (live)
- -
- Avg. volume (3M)
- 4.85M
Caris Life Sciences (CAI) Stock Price & Financial Analysis
Caris Life Sciences Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $28.80 - $32.15 |
|---|---|
| 52-Week High | $33.65 |
| 52-Week Low | $14.19 |
| Open | $29.50 |
| Volume (last close) | 3.55M |
| Average Volume (3M) | 4.85M |
| Revenue (TTM) | 989.61M |
|---|---|
| Net Income (TTM) | 104.63M |
| Free Cash Flow (TTM) | 123.96M |
| EPS (TTM) | $0.36 |
| Profit Margin | 10.57% |
| Operating Margin | 15.49% |
| Return on Equity (ROE) | 17.68% |
| Debt to Equity | 0.66 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Last Dividend Ex-Date | Jun 9, 2021 |
| Market Cap | 8.98B |
|---|---|
| Shares Outstanding | 282.89M |
| P/E Ratio (TTM) | 85.87 |
| Price to Sales (P/S) | 9.08 |
| Price to Book (P/B) | 15.18 |
| EV/EBITDA | 47.18 |
| 50-Day MA | $26.55 |
|---|---|
| 200-Day MA | $21.25 |
| 1-Year Change | −0.59% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Caris Life Sciences at a Glance
As of the Oct 15, 2026 close, Caris Life Sciences (CAI) has a market capitalization of $8.98B. The stock trades at 85.9× trailing earnings and 9.1× sales. Over the trailing twelve months it earned $104.63M on revenue of $989.61M (a 10.6% profit margin) and generated $123.96M of free cash flow. Revenue grew 85.4% year over year.
As of its latest reported balance sheet, it holds $690.91M in cash and securities against $393.15M of debt, a net cash position of $297.76M.
Caris Life Sciences does not currently pay a dividend.
The share price is down 0.6% over the past year. At $31.76 (the Oct 15, 2026 close) it sits near the top of its 52-week range of $14.19 to $33.65, above its 200-day moving average of $21.25.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $28.13, 11.4% below the Oct 15, 2026 close.
Frequently Asked Questions About Caris Life Sciences
What is the current stock price for CAI?
As of the Oct 15, 2026 close, CAI stock trades at $31.76. The 52-week range is $14.19–$33.65, with a day range of $28.80–$32.15.
What is the P/E ratio for CAI?
As of the Oct 15, 2026 close, Caris Life Sciences's trailing twelve-month (TTM) P/E ratio is 85.9, meaning investors pay $85.9 for every $1 of annual earnings. Caris Life Sciences operates in the Healthcare sector.
Does CAI pay dividends?
Caris Life Sciences does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for CAI?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for CAI is Buy. The average 12-month price target is $28.13, a 11.4% downside from the Oct 15, 2026 close of $31.76.
What is the market cap of CAI?
As of the Oct 15, 2026 close, Caris Life Sciences's market capitalization is $8.98B, classifying it as a mid-cap company. Caris Life Sciences operates in the Healthcare sector within the Biotechnology industry.